In the recently revised research report made by FMI, the barbiturate drug market is expected to record USD 492.8 million in 2024. Certain patient demographics and treatment patterns in various geographies are inducing the use of barbiturate drugs. Additionally, the rising availability of barbiturate medications for neurological disorders is also propelling expansion.
The barbiturate drug industry is forecast to expand at a CAGR of 3.20% in the ten-year time frame. This is a noticeable slowdown from its previously recorded CAGR of 5.2%. The reasons behind this growth trajectory are predicted to be its use being superseded by the benzodiazepine group for sedative or hypnotic purposes. Certain barbiturates are now widely used in the treatment of epilepsy, whereas shorter-acting molecules are being employed in anesthesia.
According to revenue analysis of the barbiturate drug market by FMI analysts for the year 2034, the sector is projected to surpass USD 675.0 million.
| Attributes | Key Insights |
|---|---|
| Industry Size (2024E) | USD 492.8 million |
| industry Valuation (2034F) | USD 675.0 million |
| Value-based CAGR (2024 to 2034) | 3.20% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Principal Consultant
In the section below, find out brimming opportunities in the barbiturate drug market, barbituric acid market, and nitric acid market. This section gives a brief comparison between associated industries and the barbiturate drug market.
Core Market:
| Attributes | Barbiturate Drug Industry |
|---|---|
| CAGR (2024 to 2034) | 3.20% |
| Growth Factor | Rising demand for long-acting barbiturates |
| Opportunity | Emerging opportunities for novel barbiturate-based analgesics |
| Key Trend | Research advancements and innovations in barbiturate discovery |
Barbituric Acid Industry:
| Attributes | Barbituric Acid Industry |
|---|---|
| CAGR (2024 to 2034) | 4.60% |
| Growth Factor | Increasing sleeping disorders, especially in countries like China and India, contribute to market expansion of barbituric acid |
| Opportunity | Expansion of pharmaceutical sector presents extensive opportunities for barbituric acid providers |
| Key Trend | Rising demand for barbituric acid in health supplements |
Nitric Acid Industry:
| Attributes | Nitric Acid Industry |
|---|---|
| CAGR (2024 to 2034) | 3.3% |
| Growth Factor | Fertilizer manufacturers are increasing their use of nitric acid |
| Opportunity | Increasing competition, propelled by many players manufacturing nitric acids, is fueling innovations |
| Key Trends | Rising use of nitric acid to meet vehicle weight reduction regulations brought by surging environmental concerns |
| Leading Drug Type | Long-acting Barbiturate |
|---|---|
| Growth Rate (From 2024 to 2034) | 3.0% |
According to FMI analysts, the long-acting barbiturate has been analyzed to attain a share of 38% in 2024. Throughout the historical period, this segment portrayed an average growth of 5%. Now in the forecast period, the segment is projected to proceed at a CAGR of 3%.
Long-acting barbiturates are finding extensive use, higher than their counterparts, to treat patients with a history of experiencing seizures and anxiety. The drug is primarily used for daytime sedation.
| Leading Application | Epilepsy |
|---|---|
| Growth Rate (From 2024 to 2034) | 2.80% |
The use of barbiturates to treat epilepsy is projected to rise at a CAGR of 2.80% over the forecast period. Comparing this to the previous recorded rate of 4.8%, the industry growth rate is slowly declining. Key reasons for this shift in preference could be the common side effects that have surfaced in the medical community regarding the use of barbiturates. As a result, new drugs are explored, or innovations are being made to substitute the use of barbiturates.
Despite recent explorations for new drugs, barbiturates are still widely used to curb episodes of epilepsy. Analysts at FMI have registered that epilepsy is in line to account for 48.8% of the industry share in 2024.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Countries | Forecast CAGR (2024 to 2034) |
|---|---|
| The United States | 3.50% |
| The United Kingdom | 4.40% |
| China | 3.90% |
| Japan | 4.90% |
| South Korea | 5.30% |
The United States leads the barbiturate drug industry. By 2034, the industry is estimated to attain USD 120.1 million, expanding at a CAGR of 3.5% over the forecast period. Key factors propelling growth are as follows:
The consumption of barbiturates is inclined to increase at a CAGR of 4.40% over the next decade in the United Kingdom. By the end of the forecast period, the demand is expected to attain a valuation of USD 27.5 million. Some factors inflecting growth are:
The barbiturate industry in China is projected to attain USD 106.8 million by 2034. Over the next decade, sales are expected to expand at a CAGR of 3.9%. Key factors supporting the industry's growth are as follows:
The Japanese barbiturate drug market is expected to register a remuneration of USD 75.0 million by 2034. For the next ten years, the sector is projected to expand at 4.9% CAGR. The industry is driven by the following elements:
The South Korean barbiturate drug market is expected to account for a revenue of USD 43.8 million by 2034. Over the projected period, the industry is estimated to expand at a CAGR of 5.3%. Key factors that have an impact on the market dynamics of barbiturates in South Korea are as follows:
Leading players are devising clear strategies to achieve significant growth ambition. They are on a consistent lookout for opportunities to create a wide product portfolio. Additionally, players are selectively enlarging their geographical coverage and refining their development pipeline to reach more customers with their enhanced portfolio.
Industry participants are further increasing their capacity to expand their bandwidth for the annual production of barbiturates. Companies are showcasing their openness to discuss potential partnerships for future expansion.
Leading contenders are focusing on research and development projects to get ahead of their competition with innovative solutions. Players are also focusing on business development teams to develop compelling strategies for growth.
Par Pharmaceutical
Par Pharmaceutical is a highly focused generic pharmaceutical firm, that is completely owned by Endo business. The company provides patients with quality medicines. In line with this, the company develops, innovates, manufactures, and commercializes its product line.
Samarth Life Science Pvt. Ltd.
Samarth Life Science Pvt. Ltd. is an acclaimed life science firm that explores, manufactures and advertises an extensive range of life-saving critical care drugs. The company is committed to offering improved results via superior products. The unique approach undertaken by Samarth is to offer innovative proprietary pharmaceuticals while catering to the unmet medical needs of patients, which is the ultimate customer.
Ethypharm
Ethypharm, a specialty pharmaceutical firm with roots in Europe, focuses on certain Central Nervous System (CNS) conditions and diseases as well as hospital injectables. Several products made by Ethypharm are indicated for sensitive products in which patients are either in a critical state or suffer from debilitating conditions like addiction or chronic pain.
Current projections of the industry indicate a valuation of USD 492.8 million in 2024.
Looking ahead to 2034, the current forecast projects a CAGR of 3.20% for the industry.
FMI predicts the sector to reach USD 675.0 million by the year 2034.
Epilepsy is predicted to hold a significant industry share during the forecast period.
South Korea presents many opportunities for investors and stakeholders operating in the industry.
Par Pharmaceutical and Samarth Life Science Pvt. Ltd are powerful players in the barbiturate drug industry.
Explore Healthcare Insights
View Reports
Barbiturate Drug Market
